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Rheumatoid arthritis (RA) is a systemic autoimmune disease primarily aﬀecting synovial joints in which the development of
autoantibodies represents a failure of normal tolerance mechanisms, suggesting a role for follicular helper T cells (TFH) in the
genesis of autoimmunity. To determine whether quantitative or qualitative abnormalities in the circulating TFH cell population
exist, we analysed by flow cytometry the number and profile of these cells in 35 patients with RA and 15 matched controls. Results
were correlated with patient characteristics, including the presence of autoantibodies, disease activity, and treatment with biologic
agents. Circulating TFH cells from patients with RA show significantly increased expression of the immunoglobulin superfamily
receptor CD200, with highest levels seen in seropositive patients (P = 0.0045) and patients treated with anti-TNFα agents (P =
0.0008). This occurs in the absence of any change in TFH numbers or overt bias towards Th1, Th2, or Th17 phenotypes. CD200
levels did not correlate with DAS28 scores (P = 0.887). Although the number of circulating TFH cells is not altered in the blood
of patients with RA, the TFH cells have a distinct phenotype. These diﬀerences associate TFH cells with the pathogenesis of RA and
support the relevance of the CD200/CD200R signalling pathway as a potential therapeutic target.
1. Introduction
Rheumatoid arthritis (RA) is a chronic, systemic autoim-
mune disease characterised by inflammation of synovial
joints [1]. The aetiology of RA is both complex and poorly
understood, and while the formation of autoantibodies such
as rheumatoid factors (RFs) or anticitrullinated protein anti-
bodies (ACPAs) is common [2, 3], their role in disease
pathogenesis remains unclear. Autoantibodies in RA are
usually of the IgG subclass and demonstrate high aﬃnity
for their targets, characteristics consistent with production
by B-cells that have undergone T-cell-dependent germinal
centre (GC)maturation [4]. A role for CD4+ T cells in disease
development is further supported by their presence in the
synovium of aﬀected patients, often with evidence of ectopic
germinal centre formation RA [5] and the association of RA
with HLA-DR4 [6, 7].
Within germinal centres, the fate of developing B cells is
determined by their ability to present antigen to a specialised
subset of CD4+ T cells termed follicular helper T cells (TFH),
located in the B-cell follicle by virtue of expression of the
chemokine receptor CXCR5 [8]. Through a combination
of cytokine secretion and highly regulated cell-cell interac-
tions, TFH cells guide the maturation of B cells, facilitat-
ing class-switching and somatic hypermutation [9]. TFH cells
also provide critical censoring functions, withdrawing help
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Table 1: Characteristics of the study population∗.
Characteristic Seropositive (n = 20) Seronegative (n = 15) Controls (n = 15) P values
Age 59.4 (33.2–90.4) 60.2 (32.7–80.9) 56.3 (22.4–84.8) 0.87
% Male 50 46.7 53.3 0.94
Lymphocytes† 1.94 (0.84–3.26) 1.95 (0.67–3.18) 2.1 (1.0–3.24) 0.95
% CD4+ 50.2 (26.8–66.9) 56.2 (37.6–68.3) 44.43 (28.5–65.4) 0.02
% CD8+ 22.3 (8.21–59.1) 17.3 (4.53–51.4) 25.97 (11.2–39.6) 0.03
CRP (mg/L) 33.7 (2–132) 30.29 (2–101) N/A 0.86
ESR (mm/hr) 24.8 (2–105) 22.2 (1–84) N/A 0.75
Creatinine (μmol/L) 80.4 (49.3–105.2) 82.8 (50.4–139.7) N/A 0.95
DAS-28 (CRP) 4.20 (0.97–6.66) 4.74 (2.10–8.63) N/A 0.84
Duration of RA 52.6 (1–232) 46.5 (1–135) N/A 0.87
Steroid therapy 6/20 6/15 N/A 0.72
DMARD therapy 16/20 9/15 N/A 0.14
Anti-TNF therapy‡ 9/20 6/15 N/A 0.77
∗
values shown are the mean and range (brackets).
†×106/mL.
‡5 patients received etanercept (3 in the seropositive and 2 in the seronegative group); the remaining patients received adalimumab.
from B cells with autoreactive potential thereby preventing
autoimmunity [10, 11]. A central role for TFH cells in the
development of autoimmune diseases has been confirmed
in animal models, where dysregulated TFH function can pro-
mote autoantibody formation [12, 13], and in humans, with
increased TFH cell numbers identified in some patients with
SLE and RA and an altered TFH phenotype demonstrable in
patients with juvenile dermatomyositis [14–17].
One of the diﬃculties of systematically studying TFH cells
in human autoimmune conditions is that historically TFH
cells were defined not only by the receptors they express
but also by their anatomical location: secondary lymphoid
organs, making routine analysis of these cells impractical
[8, 18]. However, recently circulating populations of T-helper
cells that express CXCR5 and have similar functionality to
tissue-resident TFH cells (provision of B-cell help, expression
of the transcription factor Bcl6 and the cytokine IL-21)
have been defined [16, 17]. Analysis of these cells therefore
provides an opportunity to interrogate the TFH compartment
through sampling of peripheral blood.
To determine whether TFH cells might be relevant to
the pathogenesis of RA, we examined whether quantitative
or qualitative abnormalities exist in the circulating TFH
population in patients with RA and whether these diﬀerences
might be more pronounced in seropositive patients (the
presence of class-switched autoantibodies being indicative
of TFH cell-induced maturation). In contrast to previous
work, we did not find increased numbers of circulating TFH
cells in patients with RA; however the phenotypic profile of
these cells was abnormal, with increased expression of the
inhibitory receptor CD200. Improved understanding of the
spatial and temporal regulation of stimulatory and inhibitory
receptors present on TFH cells may provide new insights into
the development of autoimmunity in RA.
2. Materials and Methods
2.1. Patient Recruitment and Clinical Samples. Patients
attending rheumatology and orthopaedic clinics were
recruited to donate whole blood following written informed
consent. Healthy controls were recruited through adver-
tisement and donated blood following written informed
consent. Research was conducted in accordance with the
Declaration of Helsinki. Ethical approval for the study
was granted by the Berkshire Research Ethics Committee
(REC reference 08/H0607/50). A total of 50 subjects were
recruited (35 patients with RA and 15 controls). All patients
fulfilled the American Rheumatological Association’s criteria
for the diagnosis of RA [19], and disease activity scores
(DAS28-CRP) were recorded for each patient at the time of
recruitment. Patients with RA were further subdivided for
analysis based on the presence of circulating autoantibodies
and treatment with anti-TNFα agents. 20 patients were
autoantibody positive; 19 had rheumatoid factor, 8 had
ACPA, and 7 patients were positive for both. Characteristics
of the study population are shown in Table 1.
2.2. Reagents. Directly conjugated anti-human antibodies
against CD3, CD4, CXCR5, CD45RO, CD69, CD95, CD134
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(OX-40), ICOS, CD200, CD150, CXCR3, CCR6, and HLA-
DR were purchased from BD Biosciences (San Jose, Califor-
nia).
2.3. Phenotypic Analysis of TFH Cells from Whole Blood. 3mL
of whole blood was washed twice with 10mL PBS (Fisher
Scientific) before centrifugation at 400 g for 5 minutes.
Following aspiration of the PBS/plasma, 100 μL aliquots were
transferred into polystyrene FACS tubes (BD Biosciences)
for staining. Directly conjugated surface antibodies were
added and cells incubated at 4◦C for 30 minutes in the
dark. Red blood cells were lysed with 2mL of BD Lyse/Fix
(BD Biosciences) for 10 minutes at 37◦C. Samples were
then washed in 3mL of 2% BSA (Fisher Scientific)/PBS and
resuspended in 150 μL of 2% Paraformaldehyde/PBS before
acquisition on a BD FACSCanto flow cytometer.
2.4. Serum Exchange Experiments. Serumwas aspirated from
clotted blood following centrifugation at 1500 g before being
snap frozen on dry ice and stored at −80◦C. For serum
exchange experiments, serum from two seropositive patients
with high TFH cell CD200 levels and two seropositive patients
with negligible TFH CD200 levels was thawed and added
to fresh PBMCs from healthy controls (without significant
CD200 expression on their TFH cells). Cells were cultured
(1× 106/well) in RPMI media containing 5% patient serum,
5% human serum (Sigma-Aldrich, Dorset, UK), or 5%
human serum supplemented with PHA (5 μg/mL).
2.5. Data Analysis. Flow cytometry was performed on a BD
FACSCanto machine using BD FACSDiva software. Flow
cytometry data were analysed using FlowJo 8.8.3 (Tree Star,
Inc., Ashland, OR). Statistical analyses were performed with
Prism 5 software (GraphPad Software, Inc. La Jolla, CA).
Normality was assessed with the D’Agostino and Pearson
test. Nonparametric data were analysed using the Mann-
Whitney or Kruskal-Wallis tests. Significance is shown as
∗ = P < 0.05, ∗∗ = P < 0.01, ∗∗∗ = P < 0.001.
3. Results/Figures
3.1. Follicular Helper T-Cell Numbers Are Not Increased
in Patients with RA. Data from animal studies and from
patients with SLE or juvenile dermatomyositis have sug-
gested important roles for TFH cells in the development
of autoimmunity. As ectopic germinal centres are common
in the synovium of patients with RA and a previous
study in treatment-naı¨ve patients with RA demonstrated
increased numbers of circulating TFH cells, we sought to
confirm whether increased numbers of circulating TFH cells
are present in patients with established disease, potentially
contributing to the breakdown in tolerance. To answer this
question, we analysed TFH numbers in whole blood from
35 patients with active RA (average age 59, range 33–90)
and 15 controls (average age 56, range 33–85) (P = 0.50).
Detailed characteristics of the study population are shown
in Table 1. As the most appropriate way to define TFH cells
in peripheral blood continues to be debated, we calculated
TFH cell numbers using four diﬀerent phenotypic defi-
nitions: (i) CD4+/CXCR5+, (ii) CD4+/CD45RO+/CXCR5+,
(iii) CD4+/CXCR5+/PD-1hi, and (iv) CD4+/CXCR5+/ICOShi
(Figure 1), as absolute cell counts (per mL of whole blood)
and as a % of total CD4+ cells (data not shown). There
was no diﬀerence in TFH cell numbers between controls or
patients with RA (including the subgroup of seropositive
patients) regardless of the definition used (P ≥ 0.4 in all
cases).
3.2. TFH Subsets Are Not Polarized toward Th1, Th2, or Th17
Phenotypes in RA. Circulating TFH cells can be further sub-
divided into three subsets based on the expression patterns
of the inflammatory chemokine receptors CXCR3 and CCR6
[17]. These subsets display functionality associated with
other T-helper cell classes (Th1, Th2, and Th17), including
expression of their characteristic cytokines and transcription
factors [17]. To determine whether TFH subsets were biased
in patients with RA, we analysed the expression of CCR6
and CXCR3 on CD4+/CXCR5+ T cells, using the definitions
of Morita et al. [17]. Th1 TFH cells were defined as being
CXCR3+/CCR6−, Th2 TFH cells as CXCR3−/CCR6−, and
Th17 TFH cells as CXCR3−/CCR6+. No biases toward a
particular TFH cell subset were detected in patients with RA
or in the subgroup of RA patients with autoantibodies (P >
0.65 for all subsets) (Figure 2).
3.3. Qualitative Diﬀerences in TFH Cells Exist in Patients with
RA. The balance between the positive and negative signals
received by a cell is critical in determining its fate. TFH cells
express both stimulatory and inhibitory receptors on their
surface that can regulate B-cell maturation and responses
to antigen [10, 20]. Therefore we asked next if qualitative
diﬀerences in receptor expression might contribute to the
development of autoreactive B cells in RA. To explore this
possibility we reviewed the expression of receptors displayed
by TFH cells, including CD200, CD150, CD134 (OX-40),
CD69, CD95, and HLA-DR. These assays revealed signifi-
cantly increased levels of the inhibitory receptor CD200 were
present in patients with RA (P = 0.0079) (Figure 3(a)). As
the presence of autoantibodies defines a distinct subset of
patients [21], we also assessed the diﬀerences in receptor
expression between seropositive and seronegative patients,
which demonstrated increased levels of both CD200 and
CD150 on TFH cells from seropositive patients with RA
(P = 0.0045 and P = 0.0088 resp.) (Figure 3(b)). Although
CD200 and CD150 upregulation could be detected on other
CD4+ T cell populations, only CD200 expression was more
pronounced on CXCR5+ cells, suggesting selective enrich-
ment in the TFH compartment (Figure 3(c)). Although there
was a trend towards increased expression of the activating
receptor OX40 (CD134) (see Supplementary Figure 1(a)
available online at doi:1155/2012/948218), there was no
enrichment in the TFH compartment or in seropositive
patients, and the diﬀerence was not statistically significant
(P > 0.05). There were no diﬀerences in the expression
of CD69, CD95, or HLA-DR (Supplementary Figures 1(a)–
1(d)).
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Figure 1: Enumeration of circulating TFH cells in whole blood. TFH cells were counted in whole blood using four diﬀerent phenotypic
definitions. (a)–(d) Representative gating strategy. (e) CD4+/CXCR5+; (f) CD4+/CD45RO+/CXCR5+; (g) CD4+/CXCR5+/PD-1hi; (h)
CD4+/CXCR5+/ICOShi. No diﬀerences were detected between patients with RA and controls (P ≥ 0.4 in all cases). Spots represent individual
patients. Mean ± SEM are shown.
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Figure 2: TFH cell subsets in RA. The % of TFH cells with Th1, Th2, or Th17 phenotypes was assessed through expression of the chemokine
receptors CXCR3 and CCR6 (see text for details). SP: seropositive, SN: seronegative. Spots represent individual patients. Mean ± SEM are
shown.
3.4. CD200 Expression Correlates with Treatment. CD200
expression is induced by inflammation, with increased levels
detected on T cells following stimulation with inflammatory
mediators, including TNFα [22]. CD200 has been proposed
to be part of a negative feedback loop (via CD200R), in
which the induction of CD200 suppresses further cytokine
release by macrophages [23]. Given the dramatic benefits
that anti-TNFα therapies have on disease progression in RA
we wondered if CD200 expression on TFH cells might itself
reflect treatment with these agents or disease activity. Levels
of CD200 on TFH cells were significantly higher in patients
receiving treatment with anti-TNFα agents (P = 0.0008)
(Figure 4(a)), regardless of whether they were seropositive
(P = 0.053-data not shown). CD200 expression was not
related to disease activity as calculated by the DAS-28 (CRP)
score (P = 0.887, r2 = 0.0009) (Figure 4(b)) or to the ACPA
titre (P = 0.896, r2 = 0.003 (data not shown)).
3.5. CD200 Expression on TFH Cells Is Not Induced by Circulat-
ing Factors. To determine whether a soluble factor could be
responsible for the increased expression of CD200, PBMCs
from healthy controls were incubated with serum from two
seropositive patients with RA known to have high levels
of CD200 on their TFH cells or two seropositive patients
with minimal TFH cell CD200 expression. CD200 levels were
analysed at baseline and then every 24 hours until 72 hours.
CD200 expression increased slightly over time under all con-
ditions, but there was no diﬀerence in the percentage of TFH
cells expressing CD200 at any time point following addition
of serum from high or low expressors (Supplementary Figure
2, P > 0.05). However, significantly increased expression
of CD200 on TFH cells was detected on freshly purified
peripheral blood mononuclear cells PBMC (F) when com-
pared with whole blood from the same donors (P = 0.004),
suggesting that the manipulation of TFH cells itself may alter
expression of the receptor (Supplementary Figure 3).
4. Discussion
This study is the first to describe an alteration in the phe-
notype of circulating follicular helper T cells in patients
6 Clinical and Developmental Immunology
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Figure 3: Analysis of receptors expressed by TFH cells. (a) Representative gating strategy showing the increased expression of CD200 on
TFH cells from patients with RA. (b) Significantly increased expression of CD200 and CD150 was detected on circulating TFH cells from
seropositive RA patients (SP: seropositive, SN: seronegative) (P = 0.0045 and P = 0.0088, resp.). Each spot represents an individual patient,
and the mean ± SEM are shown. (c) CD200 expression is enriched on CXCR5 positive CD4+ T cells in patients with RA.
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with rheumatoid arthritis. TFH cells are a distinct subset of
CXCR5-expressing CD4+ T cells that can localise to germinal
centres and are thought to maintain tolerance by censoring
B cells with specificity for self-antigens by failing to provide
the necessary cytokine and costimulatory receptor support
for their maturation [13, 24]. Dysregulation of this process
has been reported in animal models and in humans with
autoimmune diseases, particularly in conditions associated
with autoantibodies [11, 13, 14, 16, 24, 25]. Aberrant TFH cell
function is also implicated in the development of autoim-
mune phenomena in patients with angioimmunoblastic T-
cell lymphoma, a malignant proliferation of lymphocytes
that possess a TFH phenotype [26].
Given the common findings of autoantibodies and
ectopic germinal centres in patients with RA [5, 27], we
hypothesized that quantitative or qualitative abnormalities of
TFH cells may be central to the autoimmune process. As an
accepted phenotype for defining the circulating counterparts
of GC TFH cells remains controversial, we measured TFH cell
numbers in patients with RA and controls using a series
of diﬀerent phenotypic definitions. In each case TFH cell
numbers were not increased in patients with RA. This is in
contrast to the findings of Simpson et al. in patients with
systemic lupus erythematosus (SLE), where a distinct subset
of patients (∼30%) was identified as having increased TFH
cell numbers, a stable phenotype that appeared unrelated
to disease activity [16], and Ma et al. who found increased
TFH cell numbers in treatment-naı¨ve patients with RA [15].
Although SLE and RA are both systemic autoimmune dis-
eases in which autoantibody production is prominent, they
preferentially aﬀect diﬀerent organ systems, and diﬀerent
genetic loci have been implicated in their pathogenesis [28,
29]. As the average duration of RA in our patient population
was 51 months, whereas the patients in the study of Ma et
al. were newly diagnosed, one explanation for the diﬀerence
between our data and that of Ma et al. is that excess TFH cells
from the circulation may be recruited into sites of ectopic
GC formation that develop over time, resulting in normal
circulating numbers. The eﬀects of diﬀerent therapeutic
regimens on TFH development and traﬃcking may also be
relevant, and future prospective studies will help answer
these questions.
Aberrant expression of costimulatory molecules can
sustain the development of autoreactive cells causing autoim-
munity, with blockade of these receptors a proven thera-
peutic strategy [30–34]. As TFH cells are known to express
multiple receptors that mediate their interactions with B cells
[13, 24], we also investigated whether qualitative diﬀerences
in TFH cell stimulatory or inhibitory receptor expression were
present in patients with RA. Using a panel of antibodies
we identified significantly elevated levels of the inhibitory
receptors CD200 and CD150 in patients with autoantibodies
(Figure 3).
CD200 (previously known as OX-2) is a member of the
immunoglobulin gene superfamily of receptors that displays
a restricted tissue distribution, including activated T and
B cells [35]. CD200 is induced by inflammatory cytokines,
including TNFα [22], and binds to CD200R, a nonclassical
immunoglobulin family receptor found predominantly on
macrophages and dendritic cells, but also identified in
the lymph nodes and synovium of animals with collagen-
induced arthritis [36]. Binding of CD200 to CD200R causes
phosphorylation of the cytoplasmic domain of CD200R
and signalling through a series of adaptor proteins and the
MAPK pathway [37]. The consequence of this interaction
is to dampen the inflammatory response, with ligation of
CD200R a therapeutic target in collagen-induced arthritis
[23]. The importance of the CD200-CD200R axis in autoim-
munity has been confirmed in mice genetically engineered
to lack expression of CD200 or where the CD200-CD200R
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interaction is blocked, and in patients with multiple sclerosis
or androgenetic alopecia, where reduced CD200 expression
is associated with disease [38–41]. As well as limiting the
expansion of activated macrophages [42], CD200 can inhibit
NK cell function, which may be important in the pathogen-
esis of NK-mediated bone destruction in patients with RA
[43], while the expression of CD200R on B-cells suggests
the potential for CD200+ T cells to directly regulate B-cell
function [44].
Current models propose that the CD200-CD200R axis
provides a link between adaptive and innate immune
responses by regulating tissue-specific tolerance set points,
high CD200 expression serving to increase the threshold for
activation [45]. The increased expression of CD200 on TFH
cells in patients with RA may therefore represent a physio-
logical response to inflammation designed to contain auto-
reactivity [46]. To assess whether a circulating factor or
factors may be present in the serum of patients with high
TFH CD200 levels, that could be a potential biomarker, we
performed a series of serum exchange experiments (Sup-
plementary Figure 2). Serum from patients with high TFH
CD200 expression did not induce CD200 on control TFH
cells, suggesting that serum factors alone are insuﬃcient for
the induction of CD200.
As CD200 can be upregulated by TNFα [22], we assessed
whether treatment with anti-TNFα agents was related to
CD200 expression. Contrary to expectations, TFH CD200
expression was significantly higher in patients with RA
who were receiving anti-TNFα therapy (Figure 4(a)). One
potential explanation for this finding is that patients whose
disease is associated with higher TNF levels may be more
likely to respond to anti-TNFα therapy and were therefore
receiving these treatments at the time of recruitment. The
expression of CD200 on TFH cells might therefore identify
patients suited to these agents, a hypothesis that could be
tested prospectively. Although CD200 is upregulated during
inflammation, most studies have focussed on acute inflam-
mation [45]. Therefore, the failure of TFH CD200 expression
to correlate with disease activity (Figure 4(b)) may reflect
the chronicity of the inflammatory process in RA or the
presence of more complex interactions between treatment
and systemic versus local synovial TNFα concentrations.
As the traﬃcking of TFH subsets is still poorly under-
stood, one possibility is that TFH cells with proinflammatory
phenotypes are trapped within GCs, biasing the profile
seen in the peripheral circulation. Although skewing of
the distribution of TFH subsets has been implicated in the
pathogenesis of autoimmune disease [17], we were unable
to detect a bias toward a particular TFH subset in patients
with RA (Figure 2). As significant alterations in T cell
profiles can occur following density-gradient purification
(Supplementary Figure 3) [47], these eﬀects may influence
TFH cell characterization, and further studies comparing
TFH subsets in whole blood versus purified PBMC will be
important.
In conclusion, results presented here provide evidence
that TFH cells have a role in the pathogenesis of RA and
suggest that qualitative diﬀerences in the expression of inhib-
itory receptors may be important to the immune response
and eﬃcacy of treatment with anti-TNF agents. The upreg-
ulation of CD200 on TFH cells in RA patients with autoanti-
bodies and those receiving treatment with anti-TNFα ther-
apies supports a causal link between inflammation and
induction of this receptor. Future studies examining CD200
and its ligand will contribute further to our understanding
of the pathogenesis of RA and may help to identify new
therapeutic targets in this disease.
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